Cargando…

Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues

To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Pan, Calvin Q., Ji, Shibo, Yan, Gaiqin, Cheng, Jun, Liu, Shunai, Xing, Huichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818553/
https://www.ncbi.nlm.nih.gov/pubmed/33500704
http://dx.doi.org/10.3892/etm.2021.9648
_version_ 1783638859308859392
author Li, Yue
Pan, Calvin Q.
Ji, Shibo
Yan, Gaiqin
Cheng, Jun
Liu, Shunai
Xing, Huichun
author_facet Li, Yue
Pan, Calvin Q.
Ji, Shibo
Yan, Gaiqin
Cheng, Jun
Liu, Shunai
Xing, Huichun
author_sort Li, Yue
collection PubMed
description To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy. The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks. IL-21 levels at treatment week 12 in patients who achieved HBeAg loss with undetectable levels of hepatitis B virus (HBV)-DNA at week 104 were the primary endpoint and the results were compared with those of corresponding patients without such an endpoint. Furthermore, IL-21 levels at treatment week 12 in patients who achieved an HBeAg-level decline at week 104 were assessed as the secondary endpoint. Among 24 enrolled patients with SOR to ADV (n=21), telbivudine (n=2) or ETV (n=1), the median (10-90th percentile) levels of HBeAg, HBV-DNA and ALT at baseline were 2.7 (0.2-3.1) log(10) S/CO, 5.2 (3.5-7.5) log(10) IU/ml and 0.9 (0.5-3.1) upper limit of normal, respectively. Comparison of the patients with and without HBeAg loss at week 104 indicated that their mean IL-21 levels did not significantly differ at week 12 (63.0±14.4 vs. 55.9±10.5 pg/ml; P=0.26). In the secondary endpoint analyses of patients with and without HBeAg level decline, the elevated levels of IL-21 at the first 12 weeks were significantly higher in the decline group (15.6±8.3 vs. 3.1±13.2 pg/ml; P=0.03). Following adjustment for confounding factors, the elevated levels of IL-21 from baseline to week 12 independently predicted an HBeAg level decline at week 104 (odds ratio=1.137, R(2)=0.23; P=0.047). In conclusion, the serum IL-21 levels at the first 12 weeks during the salvage therapy independently predicted HBeAg level decline at treatment week 104 in patients with SOR to NAs (ClinicalTrials.gov identifier: NCT01829685; date of registration, April 2013).
format Online
Article
Text
id pubmed-7818553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-78185532021-01-25 Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues Li, Yue Pan, Calvin Q. Ji, Shibo Yan, Gaiqin Cheng, Jun Liu, Shunai Xing, Huichun Exp Ther Med Articles To investigate whether IL-21 levels predict treatment outcomes of salvage therapy among patients with suboptimal response (SOR) to nucleos(t)ide analogues (NAs), serum IL-21 levels were measured in a prospective cohort of hepatitis B e antigen (HBeAg)-positive patients with SOR to antiviral therapy. The patients switched therapy to entecavir (ETV) with or without adefovir (ADV) for 104 weeks. IL-21 levels at treatment week 12 in patients who achieved HBeAg loss with undetectable levels of hepatitis B virus (HBV)-DNA at week 104 were the primary endpoint and the results were compared with those of corresponding patients without such an endpoint. Furthermore, IL-21 levels at treatment week 12 in patients who achieved an HBeAg-level decline at week 104 were assessed as the secondary endpoint. Among 24 enrolled patients with SOR to ADV (n=21), telbivudine (n=2) or ETV (n=1), the median (10-90th percentile) levels of HBeAg, HBV-DNA and ALT at baseline were 2.7 (0.2-3.1) log(10) S/CO, 5.2 (3.5-7.5) log(10) IU/ml and 0.9 (0.5-3.1) upper limit of normal, respectively. Comparison of the patients with and without HBeAg loss at week 104 indicated that their mean IL-21 levels did not significantly differ at week 12 (63.0±14.4 vs. 55.9±10.5 pg/ml; P=0.26). In the secondary endpoint analyses of patients with and without HBeAg level decline, the elevated levels of IL-21 at the first 12 weeks were significantly higher in the decline group (15.6±8.3 vs. 3.1±13.2 pg/ml; P=0.03). Following adjustment for confounding factors, the elevated levels of IL-21 from baseline to week 12 independently predicted an HBeAg level decline at week 104 (odds ratio=1.137, R(2)=0.23; P=0.047). In conclusion, the serum IL-21 levels at the first 12 weeks during the salvage therapy independently predicted HBeAg level decline at treatment week 104 in patients with SOR to NAs (ClinicalTrials.gov identifier: NCT01829685; date of registration, April 2013). D.A. Spandidos 2021-03 2021-01-15 /pmc/articles/PMC7818553/ /pubmed/33500704 http://dx.doi.org/10.3892/etm.2021.9648 Text en Copyright: © Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Li, Yue
Pan, Calvin Q.
Ji, Shibo
Yan, Gaiqin
Cheng, Jun
Liu, Shunai
Xing, Huichun
Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
title Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
title_full Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
title_fullStr Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
title_full_unstemmed Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
title_short Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
title_sort serum il-21 levels predict hbeag decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818553/
https://www.ncbi.nlm.nih.gov/pubmed/33500704
http://dx.doi.org/10.3892/etm.2021.9648
work_keys_str_mv AT liyue serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues
AT pancalvinq serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues
AT jishibo serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues
AT yangaiqin serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues
AT chengjun serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues
AT liushunai serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues
AT xinghuichun serumil21levelspredicthbeagdeclineduringrescuetherapyinpatientswithpartialresponsetonucleostideanalogues